As of the end of 2024, cannabis remains a Schedule I controlled substance under the federal Controlled Substances Act. The DEA published a proposed rule in May 2024 to move cannabis to Schedule III and opened a hearing on the proposal on December 2, 2024, but the agency issued no final rule before the year ended. The process is still open, and the change under review would not legalize cannabis.
cannabis rescheduling dea hearing update
The 2024 cannabis rescheduling timeline
The path from recommendation to final rule runs through several federal steps. Each one has taken months.
What Does Rescheduling Do for Cannabis?
- August 2023: The Department of Health and Human Services recommended that the DEA move cannabis to Schedule III after a scientific review by the FDA.
- May 2024: The DEA published a proposed rescheduling rule in the Federal Register, its first formal step toward a change.
- July 22, 2024: The public comment period closed. Tens of thousands of comments landed in the docket.
- December 2, 2024: A DEA administrative law judge opened a hearing to take evidence on the proposal. The session ran into procedural disputes and produced no final decision.
- December 31, 2024: Cannabis was still Schedule I. No effective date had been set.
What would Schedule III change?
Schedule III covers drugs with moderate to low potential for physical dependence, such as ketamine and anabolic steroids. Moving cannabis into that tier would shift how the federal government treats it, though the shift is narrower than many headlines suggest.
Federal tax treatment
Section 280E of the Internal Revenue Code blocks businesses that traffic in Schedule I and Schedule II substances from deducting ordinary expenses. Cannabis companies pay tax on gross income instead of net income, which drives effective rates far above what other retailers face. Schedule III would remove that barrier and let licensed operators deduct payroll, rent, and other standard costs.
cannabis rescheduling update news
Research access
Schedule I status adds layers of registration and review for scientists who want to study cannabis. Schedule III drugs face fewer barriers, so clinical trials on flower and extracts would become easier to run.
What stays the same
- Cannabis stays a controlled substance. It does not become legal the way alcohol is legal.
- State-licensed recreational sales would still conflict with federal law.
- No federal framework for interstate commerce or national retail sales would appear.
- FDA approval would still be required for any product marketed as medicine.
Does rescheduling legalize cannabis?
No. Rescheduling changes the federal penalty schedule and the tax code, nothing more. A Schedule III drug is still controlled, still subject to federal trafficking rules, and still illegal to possess without a valid prescription under federal law.
Full legalization would take an act of Congress, such as removing cannabis from the Controlled Substances Act or building a federal regulatory system. That has not happened.
Why Schedule III instead of descheduling?
The CSA requires the FDA and HHS to weigh abuse potential against accepted medical use before recommending a schedule. That review found real abuse potential, so full removal from the CSA did not come out of the process. Descheduling would erase federal prohibition, which is a job for Congress rather than the DEA.
What it means for dispensary customers
For shoppers at state-licensed stores, rescheduling would change little in the short term. State programs in states with legal cannabis keep running under state law. Prices, product menus, and age limits come from state rules, not the federal schedule.
The change matters most on the business side. Tax savings from dropping 280E would free up cash that operators could put into lower prices, new stores, or better supply. Federal banking access could also improve, though rescheduling alone does not pass the SAFER Banking Act.
How the 2024 elections shifted the state map
Federal action stalled while states kept moving on their own. Florida's adult-use ballot measure won a majority but fell short of the 60% threshold it needed, so it failed. Recreational measures in North Dakota and South Dakota also failed, and Arkansas did not pass its amendment.
Nebraska voters approved two medical cannabis initiatives, which made it the latest state to set up a medical program. The state map tilts further toward a mix of medical-only and adult-use markets, with no federal consistency behind either.
What comes next?
A final rule from the DEA is the next federal milestone, and it follows the administrative hearing record. After that, expect legal challenges from groups on both sides, which can add months or years before any change takes effect.
Congress could act on its own through banking reform, descheduling bills, or a federal regulatory framework. None of those cleared both chambers in 2024. Watch the DEA docket, court filings, and new bills for the real signal.
FAQ: cannabis rescheduling update 2024
Is cannabis legal under federal law right now?
No. Cannabis sits in Schedule I alongside heroin and LSD. State laws protect consumers and businesses inside legal states, but federal prohibition has not been lifted.
When will rescheduling take effect?
Unknown. The DEA had not issued a final rule as 2024 ended, and the December hearing raised procedural questions that push the timeline out. Court appeals after a final rule could add more delay.
Can I get cannabis with a prescription after rescheduling?
Not from a state dispensary. Schedule III status sets up a path for FDA-approved cannabis medicines, not for retail flower. A doctor's recommendation under a state medical program is not a federal prescription.
Will rescheduling lower prices?
It could help over time. Removing 280E lets licensed businesses deduct normal expenses, which cuts their tax bill. Operators may pass some of that savings to customers, though no rule requires it.